Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The More Effective and the More (bio) Similar: Plerixafor and Filgrastim XM02 (tevagastrim) As First Line PBSC Mobilization Strategy in Patients with Multiple Myeloma and Lymphomas Candidate to ABMT

Daniele Laszlo, Giovanna Andreola, Aleksandra Babic, Mara Negri, Cristina Rabascio, Ambra Malerba, Monica Drera, Elezi Rufije, Giovanni Martinelli, MD

Blood (2011) 118 (21): 2994.

https://doi.org/10.1182/blood.V118.21.2994.2994

Published: 2011

Journal Articles

Quantification of Recent Bone Marrow B-Cell and Thymic T-Cell Emigrants in Chemotherapy Naïve Patients with Chronic Lymphocytic Leukemia.

Marina Motta, MD, Claudia Ghidini, PhD, Cinzia Zanotti, PhD, Marco Chiarini, PhD, Luigi Caimi, MD, Luisa Imberti, MD, Elisa Cerqui, MD, Monica Drera, MD, Giuseppe Rossi, MD

Blood (2009) 114 (22): 2353.

https://doi.org/10.1182/blood.V114.22.2353.2353

Published: 2009

Journal Articles

The Outcome of Different Types of Second-Line Therapy in Multiple Myeloma Patients Relapsing After Uniform Front-Line Treatment with High-Dose Melphalan and Autologous Stem Cell Transplantation.

Claudia Crippa, MD, Samantha Ferrari, MD, Monica Drera, MD, Marinella Calarco, MD, Antonio Regazzoli, MD, Giuseppe Rossi, MD

Blood (2009) 114 (22): 2892.

https://doi.org/10.1182/blood.V114.22.2892.2892

Published: 2009

Journal Articles

Epidemiology, Risk Factors and Outcome of 282 Bloodstream Infections among Hematological Patients: Results of a 50 Months Prospective Surveillance Study

Chiara Cattaneo, Francesca Bracchi, Salvatore Casari, Erika Borlenghi, Maria Adele Capucci, Anna Maria Pelizzari, Liana Signorini, Massimiliano De Vecchi, Monica Drera, Alessandro Re, Giampiero Carosi, Giuseppe Rossi

Blood (2008) 112 (11): 4835.

https://doi.org/10.1182/blood.V112.11.4835.4835

Published: 2008

Journal Articles

A Comprehensive Geriatric Assessment Is More Effective Than Clinical Judgement to Prospectively Identify Elderly Patients with Diffuse Large Cell Lymphoma Who Can Tolerate Full-Dose Anthracyclin-Based Treatment and Achieve the Same Outcome as Young Patients.

Alessandra Tucci, MD, Chiara Bottelli, MD, Samantha Ferrari, MD, Erika Borlenghi, MD, Monica Drera, MD, Giuseppe Rossi, MD

Blood (2007) 110 (11): 3441.

https://doi.org/10.1182/blood.V110.11.3441.3441

Published: 2007

Journal Articles

The Combined Use of Hydroxyurea and Anagrelide Allows Better Hematologic Control in Patients with Chronic Myeloproliferative Disorders and Thrombocytosis. A Report on 13 Patients with Poor Tolerance to Hydroxyurea Monotherapy.

Moira Micheletti, MD, Mariella D’Adda, MD, Monica Drera, MD, Samantha Ferrari, MSt, Giuseppe Rossi, MD

Blood (2006) 108 (11): 4892.

https://doi.org/10.1182/blood.V108.11.4892.4892

Published: 2006

NARROW

The More Effective and the More (bio) Similar: Plerixafor and Filgrastim XM02 (tevagastrim) As First Line PBSC Mobilization Strategy in Patients with Multiple Myeloma and Lymphomas Candidate to ABMT

Quantification of Recent Bone Marrow B-Cell and Thymic T-Cell Emigrants in Chemotherapy Naïve Patients with Chronic Lymphocytic Leukemia.

The Outcome of Different Types of Second-Line Therapy in Multiple Myeloma Patients Relapsing After Uniform Front-Line Treatment with High-Dose Melphalan and Autologous Stem Cell Transplantation.

Epidemiology, Risk Factors and Outcome of 282 Bloodstream Infections among Hematological Patients: Results of a 50 Months Prospective Surveillance Study

A Comprehensive Geriatric Assessment Is More Effective Than Clinical Judgement to Prospectively Identify Elderly Patients with Diffuse Large Cell Lymphoma Who Can Tolerate Full-Dose Anthracyclin-Based Treatment and Achieve the Same Outcome as Young Patients.

The Combined Use of Hydroxyurea and Anagrelide Allows Better Hematologic Control in Patients with Chronic Myeloproliferative Disorders and Thrombocytosis. A Report on 13 Patients with Poor Tolerance to Hydroxyurea Monotherapy.

Email alerts

ASH Publications

American Society of Hematology

The More Effective and the More (bio) Similar: Plerixafor and Filgrastim XM02 (tevagastrim) As First Line PBSC Mobilization Strategy in Patients with Multiple Myeloma and Lymphomas Candidate to ABMT

Quantification of Recent Bone Marrow B-Cell and Thymic T-Cell Emigrants in Chemotherapy Naïve Patients with Chronic Lymphocytic Leukemia.

The Outcome of Different Types of Second-Line Therapy in Multiple Myeloma Patients Relapsing After Uniform Front-Line Treatment with High-Dose Melphalan and Autologous Stem Cell Transplantation.

Epidemiology, Risk Factors and Outcome of 282 Bloodstream Infections among Hematological Patients: Results of a 50 Months Prospective Surveillance Study

A Comprehensive Geriatric Assessment Is More Effective Than Clinical Judgement to Prospectively Identify Elderly Patients with Diffuse Large Cell Lymphoma Who Can Tolerate Full-Dose Anthracyclin-Based Treatment and Achieve the Same Outcome as Young Patients.

The Combined Use of Hydroxyurea and Anagrelide Allows Better Hematologic Control in Patients with Chronic Myeloproliferative Disorders and Thrombocytosis. A Report on 13 Patients with Poor Tolerance to Hydroxyurea Monotherapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only